サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：単純ヘルペスウイルス治療市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年
市場調査レポート
商品コード
1303451

単純ヘルペスウイルス治療市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年

Herpes Simplex Virus Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Virus Type, By Treatment, By Route of Administration, By Distribution Channel, By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 113 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

単純ヘルペスウイルス治療市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年
出版日: 2023年07月01日
発行: TechSci Research
ページ情報: 英文 113 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の単純ヘルペスウイルス治療市場は、予測期間中に目覚ましい成長を遂げると予測されています。

これは、高齢化人口の増加、単純ヘルペス感染症やHIVのような疾患の症例の増加によるものです。さらに、新興諸国における不衛生な習慣の使用の増加と研究開発活動への投資の増加は、世界のさまざまな地域で単純ヘルペスウイルス治療の需要を大幅に増加させています。さらに、稀な疾患に対する効率的な治療に対する需要の高まりは、単純ヘルペスウイルス治療に対する需要をさらに増加させ、それによって2028年までの市場成長を促進すると予想されます。その上、新しい治療法を使用する利点に関する意識の高まりは、世界中でHSV治療に対するヘルスケア支出の増加とともに、予測期間中、単純ヘルペスウイルス治療市場をさらに支援すると予想されます。

HSV感染の有病率の増加

単純ヘルペスウイルス感染症の有病率の増加、病院内感染率の増加、新型をもたらす微生物の急速な変異は、予測期間中の市場成長を促進する主な要因です。さらに、未発達地域や新興国市場における感染症伝播の増加や清潔さの欠如が、予測期間中の単純ヘルペスウイルス治療市場をさらに促進しています。世界保健機関（WHO）によると、HSV-2に感染する女性は男性よりも多いです。2012年には、2億6,700万人の女性と1億5,000万人の男性がHSV-2に感染していると推定されています。HSV脳炎の負担の増加は、このセグメントの市場を促進すると予想されます。米国希少疾患研究機構（National Organization for Rare Disorders）によると、米国における急性脳炎の有病率は年間約2,000例で、米国で発生する脳炎の総症例の約10％を占めています。さらに、薬剤開発への注目の高まり、在宅医療環境とポイントオブケア診断の高い導入に伴う精密医療への需要の高まり、研究開発活動への投資の増加が、予測期間中の世界市場の成長を促進すると予想されます。

ヘルスケア支出の増加

製薬・ヘルスケア部門は、技術革新、ヘルスケア支出の増加、ヘルスケア施設・システムの改善により急速に成長しており、予測期間中に有利な成長が見込まれます。多くの病院、外来手術センター、診療所が世界中で先進的な機器や装置を導入しており、市場の成長を促進します。研究機関間のイニシアチブの開拓や共同研究の増加は、ウイルスに対する新しい治療法の開発を促進しており、予測期間中の市場成長を促進すると予想されます。2020年1月、スイスのローザンヌにあるEPFL、ジュネーブ大学（UNIGE）、マンチェスター大学の科学者の共同研究により、単純ヘルペス（口唇ヘルペスウイルス）の治療に有望な、糖から作られた新規の抗ウイルス材料であるビルシドが開発されました。

利用可能なカスタマイズ

TechSci Researchは、所定の市場データを使用して、企業の特定のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

  • 市場の定義
  • 市場の範囲
    • 対象市場
    • 調査対象年
    • 主要市場セグメンテーション

第2章 調査手法

  • 調査目的
  • ベースライン調査手法
  • 主要産業パートナー
  • 主要協会と二次情報源
  • 予測手法
  • データの三角測量と検証
  • 仮定と限界

第3章 エグゼクティブサマリー

  • 市場概要
  • 主要市場セグメンテーションの概要
  • 主要市場プレーヤーの概要
  • 主要地域/国の概要
  • 市場促進要因・課題・動向の概要

第4章 顧客の声

第5章 臨床試験分析

第6章 単純ヘルペスウイルス治療の世界市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • ウイルスタイプ別（HSV-1 vs HSV-2）
    • 治療薬別（薬vsワクチン）
    • 投与経路別（経口剤、点滴剤、局所剤）
    • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
    • 地域別
    • 企業別
  • 市場マップ
    • ウイルスタイプ別
    • 治療薬別
    • 投与経路別
    • 流通チャネル別

第7章 北米の単純ヘルペスウイルス治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • ウイルスタイプ別
    • 治療薬別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州の単純ヘルペスウイルス治療市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • ウイルスタイプ別
    • 治療薬別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋地域の単純ヘルペスウイルス治療市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • ウイルスタイプ別
    • 治療薬別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米の単純ヘルペスウイルス治療市場の展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • ウイルスタイプ別
    • 治療薬別
    • 投与経路別
    • 流通チャネル別
  • 南米：：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの単純ヘルペスウイルス治療市場の展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • ウイルスタイプ別
    • 治療薬別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

  • 最近の動向
  • 合併・買収
  • 製品発表

第14章 競合情勢

  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（As reported）
  • Recent Developments
  • SWOT Analysis
    • Novartis International AG
    • GlaxoSmithKline, plc.
    • Sanofi SA
    • Mylan N.V.
    • Emcure Pharmaceuticals Ltd.
    • Glenmark Pharmaceuticals Inc.
    • Fresenius Kabi AG
    • Apotex Inc.
    • Viatris Inc.
    • Teva Pharmaceuticals Industries Ltd

第15章 戦略的提言

目次
Product Code: 14594

Global Herpes Simplex Virus (HSV) Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing aging population and increased cases of diseases like Herpes Simplex infection and HIV. Additionally, the growing usage of unhygienic practices in emerging countries, along with rising investments in research and development activities, have significantly increased the demand for herpes simplex virus treatment across different parts of the globe. Moreover, the growing demand for efficient treatment for rare conditions is further expected to increase the demand for herpes simplex virus treatment, thereby fuelling market growth through 2028. Besides, growing awareness about the advantages of using new treatments, along with increasing healthcare expenditure on HSV treatment across the globe, is further expected to support the herpes simplex virus treatment market during the forecast period.

Increasing prevalence of HSV Infection

The increasing prevalence of Herpes Simplex Virus infection, along with the increasing rate of hospital-acquired infection and rapid mutations in the microorganism leading to new strains, are the major factors that will drive the growth of the market during the forecast period. Furthermore, the increasing transmission of infectious disease and lack of cleanliness in underdeveloped and developing regions are further propelling the herpes simplex virus infection treatment market during the forecast period. According to the World Health Organization, more women are infected with HSV-2 than men. In 2012, an estimated 267 million women and 150 million men were living with the infection. The rising burden of HSV encephalitis is expected to propel the market in this segment. As per the National Organization for Rare Disorders, the prevalence of acute encephalitis in the U.S. is around 2,000 cases per year, and it includes around 10% of total cases of encephalitis occurring in the U.S. Additionally, the rising focus on drug development, increasing demand for precision medicine along with high adoption of home care settings and point-of-care diagnostics, growing investments in research and development activities are expected to drive global market growth during the forecast period.

Growing Healthcare Expenditure

The pharma and healthcare sector are rapidly growing with technological innovations, increasing healthcare spending, and improving healthcare facilities and systems, which is expected to create lucrative growth during the forecast period. Many hospitals, ambulatory surgical care centers, and clinics are adopting advanced devices and equipment across the globe, which will enhance the growth of the market. Increasing initiatives and increasing collaborations between research organizations are facilitating the development of novel treatment alternatives against viruses, which is expected to boost market growth during the forecast period. In January 2020, a research collaboration between scientists from the EPFL in Lausanne, Switzerland, the University of Geneva (UNIGE), and the University of Manchester led to the development of novel antiviral materials, virucides, made from sugar that show promise for the treatment of herpes simplex (cold sore virus).

Market Segmentation

The global Herpes Simplex Virus (HSV) Treatment Market can be segmented by virus type, treatment, route of administration, distribution channel, and by region. Based on the virus type, the market can be divided into HSV-1 v/s HSV-2. Based on treatment, the market can be divided into Drugs v/s Vaccines. Based on the route of administration, the market can be differentiated into Oral, Intravenous, and Topical. Based on distribution channel, the market can be segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global herpes simplex virus treatment market on account of the growing demand for treatments due to the increasing prevalence of herpes simplex virus infection.

Market Players

Novartis International AG, GlaxoSmithKline, plc., Sanofi SA, Mylan N.V., Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Inc., Fresenius Kabi AG, Apotex Inc., Viatris Inc., Teva Pharmaceuticals Industries Ltd are some of the leading players operating in the Global Herpes Simplex Virus (HSV) Treatment Market.

Report Scope

In this report, Global Herpes Simplex Virus (HSV) Treatment systems market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Herpes Simplex Virus (HSV) Treatment Market, By Virus Type:

  • HSV-1
  • HSV-2

Herpes Simplex Virus (HSV) Treatment Market, By Treatment:

  • Drugs
    • Acyclovir
    • Valacyclovir
    • Famciclovir
    • Others
  • Vaccines
    • Simplirix
    • Others

Herpes Simplex Virus (HSV) Treatment Market, By Route of Administration:

  • Oral
  • Intravenous
  • Topical

Herpes Simplex Virus (HSV) Treatment Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Herpes Simplex Virus (HSV) Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Herpes Simplex Virus (HSV) Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 6.2.2. By Treatment (Drugs v/s Vaccines)
      • 6.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 6.2.2.2. By Vaccines (Simplirix, Others)
    • 6.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 6.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 6.2.5. By Region
    • 6.2.6. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Virus Type
    • 6.3.2. By Treatment
    • 6.3.3. By Route of Administration
    • 6.3.4. By Distribution Channel

7. North America Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 7.2.2. By Treatment (Drugs v/s Vaccines)
      • 7.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 7.2.2.2. By Vaccines (Simplirix, Others)
    • 7.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 7.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Virus Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Canada Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Virus Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Mexico Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Virus Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel

8. Europe Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 8.2.2. By Treatment (Drugs v/s Vaccines)
      • 8.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 8.2.2.2. By Vaccines (Simplirix, Others)
    • 8.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 8.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Virus Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. Germany Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Virus Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. United Kingdom Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Virus Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Italy Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Virus Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Spain Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Virus Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Asia-Pacific Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 9.2.2. By Treatment (Drugs v/s Vaccines)
      • 9.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 9.2.2.2. By Vaccines (Simplirix, Others)
    • 9.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 9.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Virus Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. India Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Virus Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Japan Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Virus Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel
    • 9.3.4. South Korea Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Virus Type
        • 9.3.4.2.2. By Treatment
        • 9.3.4.2.3. By Route of Administration
        • 9.3.4.2.4. By Distribution Channel
    • 9.3.5. Australia Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Virus Type
        • 9.3.5.2.2. By Treatment
        • 9.3.5.2.3. By Route of Administration
        • 9.3.5.2.4. By Distribution Channel

10. South America Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 10.2.2. By Treatment (Drugs v/s Vaccines)
      • 10.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 10.2.2.2. By Vaccines (Simplirix, Others)
    • 10.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 10.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Virus Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Argentina Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Virus Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Colombia Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Virus Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Middle East and Africa Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 11.2.2. By Treatment (Drugs v/s Vaccines)
      • 11.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 11.2.2.2. By Vaccines (Simplirix, Others)
    • 11.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 11.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Virus Type
        • 11.3.1.2.2. By Treatment
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By Distribution Channel
    • 11.3.2. Saudi Arabia Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Virus Type
        • 11.3.2.2.2. By Treatment
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By Distribution Channel
    • 11.3.3. UAE Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Virus Type
        • 11.3.3.2.2. By Treatment
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Company Snapshot
  • 14.3. Products & Services
  • 14.4. Financials (As reported)
  • 14.5. Recent Developments
  • 14.6. SWOT Analysis
    • 14.6.1. Novartis International AG
    • 14.6.2. GlaxoSmithKline, plc.
    • 14.6.3. Sanofi SA
    • 14.6.4. Mylan N.V.
    • 14.6.5. Emcure Pharmaceuticals Ltd.
    • 14.6.6. Glenmark Pharmaceuticals Inc.
    • 14.6.7. Fresenius Kabi AG
    • 14.6.8. Apotex Inc.
    • 14.6.9. Viatris Inc.
    • 14.6.10. Teva Pharmaceuticals Industries Ltd

15. Strategic Recommendations